Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia
Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia
The purpose of this study is to:

 -  To examine wether adjunctive atomoxetine is more effective thank placebo for
 neuropsychological measures of reaction time, motor speed, psychomotor speed, sustained
 attention, learning and memory, working memory, and executive functioning. To determine
 the effect size of atomoxetine on these neuropsychological measures for follow-up
 studies.

 -  To determine if atomoxetine has short-term benefits for improving weight gain and other
 metabolic abnormalities associated with antipsychotics.
Participants with schizophrenia or schizoaffective disorder who are competent to participate
 in the informed consent process and provide written informed consent will be enrolled into
 the study. Participants will undergo a psychiatric evaluation, which will include the
 ascertainment of demographic information, past psychiatric and treatment history, and
 Structured Clinical Interview for DSM-IV (SCID; First et al, 1997) diagnostic interviews. A
 best estimate diagnostic approach will be utilized in which information from the SCID is
 supplemented by information from family informants, previous psychiatrists, and medical
 records to generate a diagnosis.

 Clinical Assessments: The symptom assessments will include the Brief Psychiatric Rating Scale
 (BPRS; Overall and Gorham, 1961); Scale for the Assessment of Negative Symptoms (SANS;
 Andreasen, 1982); and Clinical Global Impression Scale (CGI; Guy, 1976). i) BPRS: the four
 positive symptom items - conceptual disorganization, suspiciousness, hallucinatory behavior,
 and unusual thought content - will be used to measure positive psychotic symptoms. These four
 items have been have been used to assess positive symptoms in previous studies (Kane et al,
 1988; Buchanan et al, 1998). The BPRS Anxiety/Depression Factor, consisting of the somatic
 concern, anxiety, guilt feelings, and depression items, will be used to assess dysphoria
 (Guy, 1976). The BPRS hostility and uncooperativeness items will be used to assess hostility.
 We are not including the suspiciousness item, which is traditionally part of the BPRS
 Hostility Factor (Guy, 1976), because we have included this item with the other positive
 symptom items. ii) SANS: the SANS total score, minus the global items, inappropriate affect,
 poverty of content of speech, and attention items, will be used to measure negative symptoms.
 The inappropriate affect, poverty of content of speech, and attention items are excluded as
 lacking construct validity and because factor analytic study results suggest that these items
 are not closely related to negative symptoms (Buchanan and Carpenter, 1994). iii) CGI: the
 CGI severity of illness item will be used to assess global changes.

 Safety Assessments: The safety assessments will include the Simpson-Angus Extrapyramidal
 Symptom Rating Scale (SAS; Simpson and Angus, 1970); Abnormal Involuntary Movement Scale
 (AIMS) (Guy, 1976); Barnes Akathisia Scale (BAS; Barnes, 1989) and Side Effect Checklist
 (SEC). i) SAS: a modified 11-item version of the SAS will be used to assess EPS. ii) AIMS: is
 a 12-item scale, with 7 items designed to assess abnormal facial, oral, extremity, and trunk
 movements; 3 global judgement items; and 2 current dental status items. iii) BAS : is a 4
 item scale assessing objective and subjective symptoms of akathisia. iv) SEC: is designed to
 assess vital signs and commonly occurring antipsychotic side effects. v) Changes in total
 body weight, body mass index, lipid profile, and serum glucose.

 Neurocognitive Assessments: The following neuropsychological tests will be administered: (1)
 reaction time, processing speed and efficiency, working memory-Digit Symbol, Number
 Sequencing, Letter Number Sequencing, Mental Arithmetic, Grooved Pegboard, Simple Reaction
 Time, Complex Reaction Time, Delayed Match to Sample from the Automated Neuropsychological
 Assessment Metric; (2) sustained attention and resistance to distractibility-Gordon's
 Continuous Performance Test; (3) learning and memory-California Verbal Learning Test and
 Brief Visual Memory Test; (4) executive functioning- Planning Test and Phonemic Fluency.

 2-Week Stabilization Phase: In the 2-week stabilization phase, participants will undergo
 baseline symptom, medical, safety, and neurocognitive assessments. The participants will
 undergo a physical examination; an EKG; and laboratory tests of major organ functions (i.e.,
 CBC, liver function tests, electrolytes, glucose, BUN/Creatinine, Urinanalysis (UA), and
 thyroid functions). A baseline antipsychotic level will be collected. All women will have a
 pregnancy test.

 8-Week Double-Blind Treatment Phase: Participants will be randomly assigned to atomoxetine or
 placebo using a permuted block randomization system. Treatment assignment order is random
 within each block, and the total number of participants assigned to each treatment are equal.
 The block sizes will vary in random sequence between 2 and 4. Thus, it will be difficult to
 ascertain the next treatment assignment, even if a participant becomes unblinded, while the
 imbalance of numbers between the treatment groups is kept within tight limits. The central
 unblinded pharmacist will be notified of the treatment assignment, and will inform unblinded
 pharmacists at the other sites about which study medication to dispense. Separate emergency
 unblinding envelopes for each participant will be kept in a locked cabinet at each dispensing
 pharmacy. In addition, an emergency unblinding tool will allow specific, designated staff
 (i.e., the P.I. and Co-P.I.) to log onto the randomization data base through the MPRC
 computer network and request treatment assignment for a specific participant. An electronic
 audit trail will be kept of all such unblinding requests. All unused unblinding envelopes
 must be returned unopened to the central pharmacy at the end of the study. Participants will
 receive biweekly BPRS, SANS, SAS, BAS, AIMS, Side effect, and vital sign assessments.
 Neurocognitive assessments will be performed at week 0 and week 8 or endpoint. Laboratory
 tests, antipsychotic levels, and the EKG will be repeated at 8 weeks.

 Medication Titration Schedule: The target atomoxetine dose for this study is 80 mg/day. The
 following titration schedule will be used: Week 1-2: atomoxetine 40 mg/day; Week 3-8:
 atomoxetine 80 mg/day. This titration schedule serves to enhance tolerability and minimize
 side effects. Participants randomized to placebo will receive an equal number of placebo
 tablets during the titration schedule.

 Concomitant Medications: Participants in the study will be allowed to continue on their
 medication regimen that they were taking prior to the trial. This will allow the results to
 be more generalizable. Patients must be stabilized on a single second generation
 antipsychotic, excluding clozapine, at an unchanged dose for at least 4 weeks prior to
 randomization. All participants must be on a stable dose of all other psychotropic
 medications for at least 4 weeks prior to randomization. No medication changes or changes in
 dose will be permitted during the study period.

 Because of atomoxetine's noradrenergic activity and it's modest ability to cause increases in
 blood pressure, participants on drugs that have the potential for vasopressor effects, such
 as venlafaxine or monoamine oxidase inhibitors, will be excluded.

 Participants will be allowed as needed (PRN) benztropine (1-6mg/day) for extrapyrmidal
 symptoms, lorazepam (1-6 mg/day) for anxiety, agitation or akathisia, and chloral hydrate for
 sleep (500-1000 mg/day). To minimize the effects of the PRN medications on test results,
 participants will not receive any of the above PRN medications 12 hours prior to
 neurocognitive testing. Additionally, participants requesting the use of benztopine or any
 antiparkinson agent will first be assessed with a movement rating scale to document the
 presence of EPS prior to receiving the antiparkinson agent and will not have received any
 antiparkinson agent within 12 hours prior to the movement assessment. Participants requiring
 routine use of benztropine and lorazepam will be excluded or withdrawn from the study.

 Maintenance of the Blind: For outpatients, study medication will be dispensed on a biweekly
 basis. They will be given two extra days of medication in case of a missed appointment.
 Inpatient subjects will receive their study medication daily from either the Spring Grove
 Hospital Center TRU or the Perry Point VAMHC central pharmacy. An unblinded pharmacist at
 each site will dispense all study medications. The blind will be broken only if a medical
 emergency requires this information. If this occurs, the participant will be withdrawn from
 the study.

 All raters, investigators and other staff will be blind to treatment assignment except for
 the pharmacist. The pharmacist does not participate in assessing any of the primary symptom
 or side effect dependent variables and conveys no information about treatment assignment to
 participants or staff except in a medical emergency.

 Compliance: Participants receiving 75% of their assigned medication will be considered
 compliant. The 75% criterion ensures that participants will receive adequate treatment to
 evaluate the comparative efficacy of atomoxetine and placebo. Outpatient compliance will be
 monitored through weekly pill counts and subject interviews. Medications will be dispensed on
 a weekly basis and will only be dispensed after compliance is assessed and all assessments
 are completed. Inpatient compliance will be monitored through inpatient medication records.
 If a participant is observed to have a compliance problem, then this will be discussed with
 the participant and a plan formulated to bring the participant back within the compliance
 parameter. For outpatients, the plan may include contacting the participant's caretaker or
 scheduling increased clinic visits. These monitoring procedures have been used in other MPRC
 studies and have resulted in high levels of compliance. Compliance patterns will be carefully
 monitored in each treatment group and will be described as part of any presentation of study
 results.
Inclusion Criteria:

 -  DSM-IV diagnosis of either schizophrenia or schizoaffective disorder.

 -  Caucasian or Non-Caucasian.

 -  Subjects will be currently treated with one of the new generation antipsychotics:
 olanzapine, risperidone, quetiapine, or ziprasidone.

 -  Subjects will meet a prior criteria for cognitive impairment severity. The RBANS will
 be used to determine the level of cognitive impairment.

 Exclusion Criteria:

 -  History of an organic brain disease.

 -  History of DSM-IV alcohol or substance abuse (within the last month), or DSM-IV
 alcohol or substance dependence (within the last six months).

 -  Pregnant women.

 -  Uncontrolled hypertension defined as high blood pressure exceeding 140/90 on three
 consecutive readings despite adequate treatment.

 -  Subjects receiving venlafaxine.